Final results show that the combination of nivolumab and cabozantinib remains highly effective for patients with advanced renal cell carcinoma in real-world settings. The study reported strong outcomes, with a 74% overall survival rate at 18 months. Patients had a median progression-free survival of 14 months, and the overall response rate reached 62.1%, with disease […]
The U.S. Food and Drug Administration has approved vepdegestrant for adults with advanced or metastatic ER-positive, HER2-negative breast cancer that carries ESR1 mutations, after the disease has progressed on prior endocrine therapy. The approval is based on results from the Phase 3 VERITAC-2 trial, which compared vepdegestrant with fulvestrant. In patients with ESR1 mutations, the
FDA Approves Vepdegestrant for ESR1-Mutated Advanced Breast Cancer Read More »
Researchers say new technology could help uncover how environmental chemicals may be linked to rising cases of early-onset colorectal cancer, but they caution that current findings are still uncertain. A study published in Nature Medicine found a possible association between the herbicide picloram and colorectal cancer in younger adults. The research used molecular fingerprinting, an
New Study Explores Possible Link Between Pesticides and Early-Onset Colorectal Cancer Read More »
A new study has identified FLT1 (VEGFR1) as a key driver of tumor growth in clear cell renal cell carcinoma. Researchers found that cancer cells release VEGFA, which activates FLT1 in nearby blood vessel cells, creating signals that promote tumor growth and weaken immune responses. This interaction triggers cellular senescence, where cells stop dividing but
A new targeted therapy called ozuriftamab vedotin (Oz-V) is showing strong potential for patients with advanced HPV-related throat cancer who have already tried multiple treatments. This drug is a type of antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. What makes Oz-V unique is its ability to activate only in the acidic environment
Researchers at the Mayo Clinic have developed a new blood test that could improve the detection of germ cell tumors, the most common type of testicular cancer. This method is designed to find cancers that are often missed by standard tumor marker tests. The study introduced two tools based on immune system signals. One test,
New Blood Test from Mayo Clinic Shows High Accuracy in Detecting Testicular Cancer Read More »
Early results from a Phase 1/2 clinical trial suggest that ozekibart (INBRX-109), a targeted antibody, may offer a new option for patients with advanced colorectal cancer who have already received multiple treatments. When combined with standard chemotherapy (FOLFIRI), the drug showed stronger activity than typically seen in late-stage settings. Among 45 patients, about 20% experienced
Ozekibart Combo Shows Promising Early Results in Heavily Pretreated Colorectal Cancer Read More »
On April 30, 2026, the U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee reviewed a new treatment for advanced prostate cancer. The therapy combines capivasertib (Truqap) with abiraterone (Zytiga) for patients whose cancer has a PTEN gene loss. The decision is based on results from a large Phase 3 study called CAPItello-281. The trial
A study found a metabolic “off-switch” involved in early pancreatic cancer development. The research centers on mutations in the KRAS gene. Scientists discovered that reduced activity of two enzymes, G6PD and ME1, lowers production of NADPH, a key molecule that protects cells. This causes a buildup of reactive oxygen species, leading to cell damage and
Metabolic “Off-Switch” Discovery Offers New Path to Prevent Pancreatic Cancer Read More »
A new study has identified the protein SLC5A11 as the key reason the diabetes drug metformin can also work as a cancer treatment. Researchers used a genome-wide CRISPR screen and found that metformin must bind to SLC5A11 to trigger its anti-cancer effects. Without this protein, the drug loses its ability to work against tumors. The
SLC5A11 Identified as Key Target Behind Metformin’s Cancer-Fighting Effects Read More »